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1. INTRODUCTION {#mgg3720-sec-0005}
===============

Polycystic kidney disease (PKD) is a group of monogenic disorders that result in renal cyst development. Based on genetic patterns, PKD can be classified into autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (Harris & Torres, [2009](#mgg3720-bib-0013){ref-type="ref"}). ADPKD is the most prevalent monogenic hereditary kidney disorder and the most common monogenic disorder that causes end‐stage renal disease (ESRD) (Torres, Harris, & Pirson, [2007](#mgg3720-bib-0038){ref-type="ref"}). Its major presentations are multiple renal cysts that result in enlarged and irregular shaped kidneys. Depending on geographical location, its incidence is approximately 1:400--4000 (Torres et al., [2007](#mgg3720-bib-0038){ref-type="ref"}). ADPKD develops primarily from PKD1 gene \[MIM\#601313\] mutations on chromosome 16 and/or the PKD2 gene \[MIM\#173910\] on chromosome 4 (Listed, [1994](#mgg3720-bib-0020){ref-type="ref"}; Mochizuki et al., [1996](#mgg3720-bib-0024){ref-type="ref"}). Clinical data indicate that PKD1 and PKD2 mutations account for 85% and 15% of ADPKD patients, respectively (Rossetti et al., [2007](#mgg3720-bib-0034){ref-type="ref"}). ADPKD is heterogeneous with regard to locus and allele heterogeneity and phenotypic variability. PKD is usually bilateral, while unilateral PKD is rare. Unilateral PKD typically refers to segmental cystic abnormalities in 1 kidney. At present, few studies exist on unilateral PKD, and its pathological examination results are the same as those of ADPKD (Gouldesbrough & Fleming, [1998](#mgg3720-bib-0012){ref-type="ref"}). Over time, unilateral PKD can change to bilateral PKD and further cause ESRD (Punia, Mohan, Bal, & Bansal, [2005](#mgg3720-bib-0031){ref-type="ref"}). The pathogenesis of unilateral PKD and whether it is associated with gene mutations are unclear.

Currently, most ADPKD patients have PKD1 and/or PKD2 mutations; however, these mutations remain undetected in some patients. To better understand whether other genes cause ADPKD, as well as their resulting phenotypes, and to understand whether unilateral PKD is associated with gene mutations, we performed gene sequencing on PKD patients. Targeted next‐generation sequencing (NGS) was performed to screen 63 renal ciliopathy‐associated gene mutations in these patients.

2. MATERIALS AND METHODS {#mgg3720-sec-0006}
========================

2.1. Study design {#mgg3720-sec-0007}
-----------------

Gene sequencing was performed on 47 patients using our developed kidney disease panel. Possible pathogenic mutation sites were detected by Sanger sequencing. For some patients who did not detect suspected pathogenic genes, we further sequenced all exons and screened for suspected mutant genes. In addition, blood samples provided by family members of patients were used for segregation analyses. The detected mutation sites were carefully compared with the ADPKD Mutation Database (<http://pkdb.mayo.edu>), HGMD Professional (<https://www.qiagenbioinformatics.com>/products/human‐gene‐mutation‐database/) and relevant literature, and the mutation site pathogenicity were analyzed.

2.2. Patients {#mgg3720-sec-0008}
-------------

Forty‐seven unrelated PKD patients treated at the Chinese People\'s Liberation Army General Hospital between 2016 and 2017 were enrolled. All patients were confirmed to have unilateral or bilateral PKD by abdominal computed tomography or color Doppler ultrasound and volunteered for gene detection. The ages at PKD confirmation in these patients were 3--58 years. Forty‐four patients had bilateral PKD, and three had unilateral PKD. Among 44 bilateral PKD patients, 30 had clear family histories of dominant inheritance; therefore, validation was performed on immediate family members of 34 patients (a total of 65 family members). The three unilateral PKD patients were all isolated cases with no family history of this disease, and their parents did not have consanguineous marriages. All subjects or their legal guardians signed informed consent for genetic testing. The genetic analysis was approved by the Ethics Committee of the People\'s Liberation Army General Hospital (China).

2.3. Targeted NGS panel {#mgg3720-sec-0009}
-----------------------

Target region capture and next‐generation human gene analysis technology were performed for ciliopathy‐associated gene region and bioinformatics analyses. A kidney disease‐associated gene analysis panel including 63 genes was developed (Table [S1](#mgg3720-sup-0002){ref-type="supplementary-material"}). Combined with data including disease history and imaging examination, patients with kidney diseases and urinary system abnormalities could be screened at an early stage to reduce the damage of chronic kidney disease and provide gene diagnosis basis for personalized drugs in patients. This panel included many disease‐associated gene analyses including PKD, renal tuberculosis, Joubert syndrome, Meckel syndrome, short rib‐polydactyly syndrome (asphyxiating thoracic dysplasia/Jeune\'s syndrome), Bardet‐Biedl syndrome, and cranioectodermal dysplasia.

Targeted NGS panel was used for genetic analyses. NGS was performed on the NextSeq 500 apparatus (Illumina). This program included five main steps. (a) Nucleic acid extraction was performed on sample DNA using a genomic DNA extraction reagent kit, and the level of DNA quality was identified per the standard in Table [S2](#mgg3720-sup-0003){ref-type="supplementary-material"}. If the sample grade was level D, the sample was disqualified, and blood samples were collected again for DNA extraction. (b) The genomic library was constructed. Sample DNA was sheared to the range of 100--700 bp using the Covaris shearing method. The terminus was repaired, and an "A" was added. The product was purified for PCR amplification of the gene library, and the quality was detected per the standard in Table [S3](#mgg3720-sup-0004){ref-type="supplementary-material"}. If the sample grade was level D, the sample was disqualified and blood samples were collected again per the above procedures. (c) The target genes were captured. GenCap^®^ Kidney disease gene capture probe (MyGenostics, China) and library DNA were hybridized under set conditions. Streptavidin‐modified magnetic beads were used to covalently bind to biotin‐labeled probes to capture target genes. Finally, a magnetic separator rack was used to adsorb magnetic beads that carried target genes. Target genes were then eluted, purified, and enriched. (d) The NextSeq 500 tabletop sequencer was used for large‐scale sequencing. (e) Data analyses were performed using BWA software (<http://bio-bwa.sourceforge.net/>), GATK software (<http://www.broadinstitute>. org/gsa/wiki/index.php/GATK_resource_bundle), and ANNOVAR software (<http://www.broadinstitute.org/gsa/wiki/index.php/GATK_resource_bundle>). After comparison with Homo sapiens (hg19), a mutation site that satisfied the following conditions was screened: (a) it was present in target regions; (b) it caused amino acid changes; (c) its mutation frequency in the local population was lower than 15%; and (d) if known in the databases, its minor allele frequency was below 1% for autosomal recessive inheritance and 0.2% for autosomal dominant transmission. All filtered variants were further analyzed using Alamut v.2.9.0 software (Interactive Biosoftware, La Rochelle, France) for predicting functional effects with SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing finder, Polyphen‐2, SIFT, MutationTaster, Align GVGD and UMD‐Predictor (Morais et al., [2017](#mgg3720-bib-0025){ref-type="ref"}).

2.4. Whole exome sequencing {#mgg3720-sec-0010}
---------------------------

Genomic DNA was isolated from lymphocytes and subjected to exome capture using the SureSelect Human All ExonV6 human exome capture arrays (Agilent) followed by next generation sequencing on the NextSeq 500 tabletop sequencer. Data analyses were performed following the procedure of targeted NGS panel‐based analysis.

2.5. Sanger sequencing {#mgg3720-sec-0011}
----------------------

After gene mutation sites were detected using NGS, they were validated using Sanger sequencing. In addition, blood samples provided by the patients' family members were also validated by Sanger sequencing. Primers were designed using Primer software for PCR amplification. Next, capillary electrophoresis sequencing was performed using a 3130XL sequencer. When reference sequences were found, the reference sequences and raw data were analyzed using Mutation Surveyor software (<https://softgenetics.com/mutationSurveyor.php>).

2.6. Multiplex ligation‐dependent probe amplification {#mgg3720-sec-0012}
-----------------------------------------------------

In order to confirm the presence of large gene rearrangements in the HNF1B gene we performed multiplex ligation‐dependent probe amplification (MLPA) using the MLPA kit P241 25R (HRC‐Holland, Amsterdam, Netherlands).

3. RESULTS {#mgg3720-sec-0013}
==========

3.1. Genetic characterization {#mgg3720-sec-0014}
-----------------------------

Among 44 bilateral PKD patients (Table [1](#mgg3720-tbl-0001){ref-type="table"}), PKD1 heterozygous mutations were detected in 35 patients, PKD2 heterozygous mutations were detected in three patients, both PKD1 and PKD2 mutations were detected in three patients, one PKD1 heterozygous mutation and one PKHD1 (2‐point mutation sites) compound heterozygous mutation were detected in one patient, and HNF1B heterozygous mutations were detected in two patients. The MLPA results of P43 further confirmed the heterozygous deletion of exon 1‐9, that is, the complete HNF1B heterozygous deletion.(Figure [S1](#mgg3720-sup-0001){ref-type="supplementary-material"}) Among three unilateral PKD patients (Table [2](#mgg3720-tbl-0002){ref-type="table"}), one HNF1B heterozygous mutation was detected in one patient, and no clear pathogenic gene mutations were detected in two patients. Whole exome sequencing (WES) was performed on patient P47, and the results showed that this patient had three heterozygous mutations in LYZ, FGA, and GLI3. Sanger sequencing validation was performed on the patient\'s father, who had a heterozygous mutation at the LYZ site but normal FGA and GLI3. Because a blood sample could not be collected from the patient\'s mother, Sanger validation was not performed. We do not think the heterozygous mutations detected in the autosomal recessive genes were significant in the disease\'s development and progression.

###### 

The mutation sites in 44 bilateral PKD patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family No.                    Mutated gene   Inheritance   Exon           Nucleotide change            Amino acid change      Status   Segregation tested                                             Reference                                                                           Clinical significance
  ----------------------------- -------------- ------------- -------------- ---------------------------- ---------------------- -------- -------------------------------------------------------------- ----------------------------------------------------------------------------------- -----------------------
  \(a\) *PKD1 mutations*                                                                                                                                                                                                                                                                    

  P1                            PKD1           Dominant      exon45         c.12310A\>C                  p.Ile4104Leu           Het      Yes                                                            This study                                                                          Likely neutral

  PKD1                          Dominant       exon15        c.4340C\>T     p.Ala1447Val                 Het                    Yes      Yu et al. ([2011](#mgg3720-bib-0042){ref-type="ref"})          Likely neutral                                                                      

  P2                            PKD1           Dominant      exon40         c.11372_11373insGA\          p.Gly3791fs            Het      Yes                                                            PKDB                                                                                Definitely pathogenic
                                                                            TTACGACGTTGGCTGGGAG\                                                                                                                                                                                            
                                                                            AGTCCTCACAATGG                                                                                                                                                                                                  

  P3                            PKD1           Dominant      exon23         c.A8471C                     p.Gln2824Pro           Het      Yes                                                            This study                                                                          Likely neutral

  P4                            PKD1           Dominant      exon18         c.7288C\>T                   p.Arg2430X             Het      Yes                                                            Phakdeekitcharoen et al. ([2000](#mgg3720-bib-0030){ref-type="ref"})                Definitely pathogenic

  P5                            PKD1           Dominant      exon13         c.3140C\>A                   p.Ser1047X             Het      Yes                                                            This study                                                                          Likely pathogenic

  P6                            PKD1           Dominant      exon15         c.4306C\>T                   p.Arg1436X             Het      Yes                                                            Garcia‐Gonzalez et al. ([2007](#mgg3720-bib-0011){ref-type="ref"})                  Definitely pathogenic

  P7                            PKD1           Dominant      exon36         c.10678G\>A                  p.Gly3560Arg           Het      No                                                             Tsuchiya et al. ([2001](#mgg3720-bib-0039){ref-type="ref"})                         Likely neutral

  P8                            PKD1           Dominant      exon31         c.10081G\>A                  p.Gly3361Arg           Het      Yes                                                            This study                                                                          Likely neutral

  P9                            PKD1           Dominant      exon6          c.1291C\>T                   p.Gln431X              Het      Yes                                                            This study                                                                          Likely pathogenic

  P10                           PKD1           Dominant      exon21         c.7984C\>T                   p.Gln2662X             Het      Yes                                                            PKDB                                                                                Definitely pathogenic

  P11                           PKD1           Dominant      exon16         c.6935C\>T                   p.Ala2312Val           Het      Yes                                                            PKDB                                                                                Likely neutral

  P12                           PKD1           Dominant      exon28         c.9637T\>G                   p.Phe3213Val           Het      Yes                                                            This study                                                                          Likely neutral

  PKHD1                         Recessive      exon38        c.6245C\>T     p.Thr2082Ile                 Het                    Yes                                                                     Likely neutral                                                                      

  PKHD2                         Recessive      exon32        c.4844C\>T     p.Thr1615Met                 Het                    Yes                                                                     Likely neutral                                                                      

  P13                           PKD1           Dominant      exon1          c.108dupC                    p.Cys37Leufs\*77       Het      No                                                             Rossetti et al. ([2012](#mgg3720-bib-0035){ref-type="ref"})                         Definitely pathogenic

  P14                           PKD1           Dominant      exon23         c.8311G\>A                   p.Glu2771Lys           Het      Yes                                                            Rossetti et al. ([2000](#mgg3720-bib-0036){ref-type="ref"})                         Likely pathogenic

  P15                           PKD1           Dominant      exon10         c.2039A\>T                   p.Tyr680Phe            Het      Yes                                                            Liu et al. ([2014](#mgg3720-bib-0022){ref-type="ref"})                              Likely neutral

  P16                           PKD1           Dominant      exon15         c.4810G\>A                   p.Val1604Met           Het      Yes                                                            Yu et al. ([2011](#mgg3720-bib-0042){ref-type="ref"})                               Likely neutral

  P17                           PKD1           Dominant      exon36         c.10678G\>A                  p.Gly3560Arg           Het      No                                                             Tsuchiya et al. ([2001](#mgg3720-bib-0039){ref-type="ref"})                         Likely neutral

  P18                           PKD1           Dominant      exon23         c.8426_8428del               p.2809_2810del         Het      Yes                                                            This study                                                                          Likely neutral

  P19                           PKD1           Dominant      exon15         c.5014_5015del               p.Arg1672Glyfs\*9      Het      Yes                                                            Watnick et al. ([1999](#mgg3720-bib-0040){ref-type="ref"})                          Definitely pathogenic

  P20                           PKD1           Dominant      exon15         c.6544C\>T                   p.Gln2182X             Het      Yes                                                            This study                                                                          Likely pathogenic

  P21                           PKD1           Dominant      exon25         c.9136C\>T                   p.Arg3046Cys           Het      Yes                                                            Liu et al. ([2015](#mgg3720-bib-0021){ref-type="ref"})                              Likely pathogenic

  PKD1                          Dominant       exon15        c.6915+2T\>G   splicing                     Het                    Yes      Perrichot et al. ([2000](#mgg3720-bib-0029){ref-type="ref"})   Definitely pathogenic                                                               

  P22                           PKD1           Dominant      exon23         c.8464G\>A                   p.Val2822Met           Het      Yes                                                            Hwang et al. ([2016](#mgg3720-bib-0017){ref-type="ref"})                            Likely neutral

  P23                           PKD1           Dominant      exon45         c.12142G\>T                  p.Val4048Leu           Het      Yes                                                            This study                                                                          Likely neutral

  PKD1                          Dominant       exon25        c.9157G\>A     p.Ala3053Thr                 Het                    Yes      Chang et al. ([2013](#mgg3720-bib-0004){ref-type="ref"})       Likely pathogenic                                                                   

  PKD1                          Dominant       exon10        c.2039A\>T     p.Tyr680Phe                  Het                    Yes      Liu et al. ([2014](#mgg3720-bib-0022){ref-type="ref"})         Likely neutral                                                                      

  P24                           PKD1           Dominant      exon23         c.8464G\>A                   p.Val2822Met           Het      Yes                                                            Hwang et al. ([2016](#mgg3720-bib-0017){ref-type="ref"})                            Likely neutral

  PKD1                          Dominant       exon39        c.11258G\>C    p.Arg3753Pro                 Het                    Yes      This study                                                     Likely pathogenic                                                                   

  P25                           PKD1           Dominant      exon26         c.9272T\>G                   p.Met3091Arg           Het      Yes                                                            This study                                                                          Likely neutral

  PKD1                          Dominant       exon11        c.2527T\>C     p.Ser843Pro                  Het                    Yes      Yu et al. ([2011](#mgg3720-bib-0042){ref-type="ref"})          Likely neutral                                                                      

  P26                           PKD1           Dominant      exon44         c.12138+5G\>A                splicing               Het      Yes                                                            This study                                                                          Likely neutral

  PKD1                          Dominant       exon36        c.10678G\>A    p.Gly3560Arg                 Het                    Yes      Tsuchiya et al. ([2001](#mgg3720-bib-0039){ref-type="ref"})    Likely neutral                                                                      

  P27                           PKD1           Dominant      exon23         c.8295_8296insATCCTCATGCGC   p.Ser2766delinsILMRS   Het      Yes                                                            Rossetti et al. ([2000](#mgg3720-bib-0036){ref-type="ref"})                         Definitely pathogenic

  P28                           PKD1           Dominant      exon40         c.11314delG                  p.Ala3772Profs\*54     Het      Yes                                                            Liu et al. ([2015](#mgg3720-bib-0021){ref-type="ref"})                              Definitely pathogenic

  P29                           PKD1           Dominant      exon33         c.10321C\>T                  p.Gln3441X             Het      Yes                                                            Obeidova et al. ([2014](#mgg3720-bib-0026){ref-type="ref"})                         Definitely pathogenic

  P30                           PKD1           Dominant      exon36         c.10678G\>A                  p.Gly3560Arg           Het      Yes                                                            Tsuchiya et al. ([2001](#mgg3720-bib-0039){ref-type="ref"})                         Likely neutral

  PKD1                          Dominant       exon43        c.11944C\>T    p.Gln3982X                   Het                    Yes      Rossetti et al. ([2007](#mgg3720-bib-0034){ref-type="ref"})    Definitely pathogenic                                                               

  P31                           PKD1           Dominant      exon7          c.1591G\>A                   p.Glu531K              Het      Yes                                                            Hwang et al. ([2016](#mgg3720-bib-0017){ref-type="ref"})                            Likely neutral

  P32                           PKD1           Dominant      exon21         c.7985dupA                   p.Gln2663Alafs\*159    Het      Yes                                                            This study                                                                          Likely pathogenic

  P33                           PKD1           Dominant      exon5          c.862C\>T                    p.Gln288X              Het      Yes                                                            Bataille, Berland, Fontes, and Burtey ([2011](#mgg3720-bib-0003){ref-type="ref"})   Definitely pathogenic

  P34                           PKD1           Dominant      exon15         c.3792C\>A                   p.Tyr1264X             Het      No                                                             PKDB                                                                                Definitely pathogenic

  P35                           PKD1           Dominant      exon8          c.1722+1G\>C                 splicing               Het      No                                                             Audrézet et al. ([2012](#mgg3720-bib-0002){ref-type="ref"})                         Definitely pathogenic

  P36                           PKD1           Dominant      exon18         c.7300C\>T                   p.Arg2434Trp           Het      Yes                                                            Hoefele, Mayer, Scholz, and Klein ([2011](#mgg3720-bib-0016){ref-type="ref"})       Likely pathogenic

  \(b\) *PKD2 mutations*                                                                                                                                                                                                                                                                    

  P37                           PKD2           Dominant      exon4          c.1094+1G\>A                 splicing               Het      Yes                                                            Chung et al. ([2010](#mgg3720-bib-0006){ref-type="ref"})                            Definitely pathogenic

  P38                           PKD2           Dominant      exon4          c.964C\>G                    p.Arg322Gly            Het      Yes                                                            Audrézet et al. ([2015](#mgg3720-bib-0001){ref-type="ref"})                         Likely pathogenic

  P39                           PKD2           Dominant      exon5          c.1249C\>T                   p.Arg417X              Het      Yes                                                            Pei et al. ([1998](#mgg3720-bib-0027){ref-type="ref"})                              Definitely pathogenic

  \(c\) *PKD1&PKD2 mutations*                                                                                                                                                                                                                                                               

  P40                           PKD1           Dominant      exon23         c.8444C\>T                   p.Ala2815Val           Het      No                                                             Yu et al. ([2011](#mgg3720-bib-0042){ref-type="ref"})                               Likely neutral

  PKD1                          Dominant       exon18        c.7480G\>A     p.Glu2494Lys                 Het                    No       This study                                                     Likely neutral                                                                      

  PKD2                          Dominant       exon6         c.1546G\>T     p.Val516Leu                  Het                    No       Yu et al. ([2011](#mgg3720-bib-0042){ref-type="ref"})          Likely neutral                                                                      

  P41                           PKD2           Dominant      exon10         c.2051dupA                   p.Tyr684_S685delinsX   Het      Yes                                                            This study                                                                          Likely pathogenic

  PKD1                          Dominant       exon37        c.10973A\>G    p.Lys3658Arg                 Het                    Yes      This study                                                     Likely neutral                                                                      

  P42                           PKD2           Dominant      exon10         c.2083dupA                   p.Ala696Sfs\*2         Het      Yes                                                            This study                                                                          Likely pathogenic

  PKD1                          Dominant       exon36        c.10678G\>A    p.Gly3560Arg                 Het                    Yes      Tsuchiya et al. ([2001](#mgg3720-bib-0039){ref-type="ref"})    Likely neutral                                                                      

  \(d\) *HNF1B mutations*                                                                                                                                                                                                                                                                   

  P43                           HNF1B          Dominant      exon1−9        Complete deletion            Complete deletion      Het      No                                                                                                                                                  

  P44                           HNF1B          Dominant      exon4          c.894_895delCT               p.Asn298Lysfs\*21      Het      No                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

The mutation sites in three unilateral PKD patients

  Family No.   Mutated gene   Inheritance   Exon         Nucleotide change   Amino acid change   Status   Mutation frequency in the local population   Clinical significance
  ------------ -------------- ------------- ------------ ------------------- ------------------- -------- -------------------------------------------- -----------------------
  P45          HNF1B          Dominant      exon1        c.313G\>A           p.Glu105Lys         het      0.00217                                      Uncertain
  ZNF423       Recessive      exon4         c.2237A\>G   p.Lys746Arg         het                 0.0001   VUS                                          
  P46          ALMS1          Recessive     exon8        c.2351A\>G          p.Flu784Gly         het      0.0068                                       VUS
  BBS2         Recessive      exon8         c.865A\>G    p.Ile289Val         het                 0.0174   VUS                                          
  BBS9         Recessive      exon19        c.2086G\>A   p.Asp696Asn         het                 0.0068   VUS                                          
  CSPP1        Recessive      exon27        c.3298T\>C   p.Trp1100Arg        het                 0.0308   VUS                                          
  IFT122       Recessive      exon30        c.3686G\>A   p.Arg1229His        het                 0.0016   VUS                                          
  TTC8         Recessive      exon14        c.1328G\>A   p.Arg443Gln         het                 ---      VUS                                          
  P47          CEP290         Recessive     exon38       c.5127G\>T          p.Gln1709His        het      ---                                          VUS
  NPHP4        Recessive      exon10        c.1196A\>G   p.Glu399Gly         het                 0.0026   VUS                                          
  PKHD1        Recessive      exon28        c.3179A\>G   p.Asn1060Ser        het                 ---      VUS                                          

John Wiley & Sons, Ltd

Forty‐eight mutation sites were detected in the PKD1 and PKD2 genes (Table [1](#mgg3720-tbl-0001){ref-type="table"}). Compared with PKDB, HGMD Professional and literature reports, we found a total of 18 novel variants (16 in PKD1 and two in PKD2). All mutation sites were analyzed for pathogenicity in strict accordance with the American College of Medical Genetics and Genomics guidelines. Sixteen definite pathogenic mutation types (14 PKD1 gene sites and two PKD2 gene sites) were detected in 16 probands. These mutations included eight nonsense, four frameshift, three splicing, and one insertion mutation. We speculated that the splicing mutation (c.1722+1G\>C, splicing) in PKD1 was a novel pathogenic mutation. There were 12 likely pathogenic mutations (nine PKD1 and three PKD2 gene sites) in 12 probands. These mutations included four nonsense, two frameshift, and six missense mutations. We predicted seven novel, likely pathogenic mutations (five PKD1 and two PKD2 gene sites) (Table [1](#mgg3720-tbl-0001){ref-type="table"}). There were 20 likely neutral mutations (19 PKD1 and 1 PKD2 gene site) in 20 probands. These mutations included 18 missense, one splicing, and one frameshift mutation. We predicted 10 novel, likely neutral mutations (10 PKD1 gene sites) (Table [1](#mgg3720-tbl-0001){ref-type="table"}).

3.2. Clinical manifestation {#mgg3720-sec-0015}
---------------------------

Among 42 patients with bilateral PKD caused by PKD1 and/or PKD2 mutations, 11 (26.2%) had combined hepatic cysts or polycystic liver. Some had already progressed to ESRD and required renal replacement therapy. Two with HNF1B mutations had no combined hepatic cysts, and their kidney functions were within the normal range. P44 had type 2 diabetes mellitus, while P43 had no history of diabetes mellitus but had increased uric acid (blood uric acid: 553.5 µmol/L). The three patients with unilateral PKD had a left polycystic kidney with normal morphology of the right kidney. P45 had no history of diabetes mellitus but had increased blood creatinine and uric acid (blood creatinine: 122.6 µmol/L; blood uric acid: 613 µmol/L). This patient\'s father also had a heterozygous mutation at the same HNF1B gene site (Table [2](#mgg3720-tbl-0002){ref-type="table"}); however, the father had normal bilateral kidney morphology with no history of diabetes mellitus. The other two unilateral PKD patients (P46 and P47) with no detected pathogenic genes had normal creatinine and no family history of cystic diseases.

4. DISCUSSION {#mgg3720-sec-0016}
=============

NGS can target the whole genome for detection. It has the advantages of high resolution, high throughput, high efficiency, and high sensitivity. It can increase gene detection efficiency and reduce gene detection costs (Mardis, [2008](#mgg3720-bib-0023){ref-type="ref"}). After mutation sites are detected by NGS, Sanger sequencing validation can further increase detection accuracy; however, NGS cannot detect deleted or repeated fragments in nucleic acid sequences. Therefore, for typical ADPKD patients whose gene mutations cannot be detected by NGS, MLPA should be used to detect whether PKD1 or PKD2 have deleted or repeated fragments to avoid missed diagnoses. Synonymous mutations are generally considered not to affect amino acid changes in proteins, However, if a silent mutation in exonic splicing enhancer sequences may affect the splicing of MRNA (Ramser et al., [2005](#mgg3720-bib-0032){ref-type="ref"}). Therefore, we need to make relevant analysis and prediction.

At present, diagnosis of ADPKD is based on family history and ultrasound imaging. In families of unknown genotype, the presence of three or more (unilateral or bilateral) renal cysts is sufficient for establishing the diagnosis in individuals aged 15--39 years, two or more cysts in each kidney is sufficient for individuals aged 40--59 years, and four or more cysts in each kidney is required for individuals 60 years (Pei et al., [2009](#mgg3720-bib-0028){ref-type="ref"}). Which lead to a delay in or lack of diagnosis of ADPKD patients with no cysts in the kidneys and no apparent family history, which may result in inappropriate management. With the development of genetic testing technology, it is possible to make a definitive diagnosis before the onset age of a patient. Genotypes can also provide the basis for disease progression and prognosis (Jin et al., [2016](#mgg3720-bib-0018){ref-type="ref"}). Based on our research and clinical experience, we designed the diagnosis process for patients with a positive family history (Figure [1](#mgg3720-fig-0001){ref-type="fig"}).

![The diagnosis process for patients with a positive family history. ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; MLPA, multiplex ligation‐dependent probe amplification; NGS, next‐generation sequencing; WES, whole exome sequencing](MGG3-7-e720-g001){#mgg3720-fig-0001}

Applying our developed targeted NGS panel detected a pathogenic gene that caused this disease in 44 bilateral PKD patients. Forty‐two patients had detected PKD1 and/or PKD2 gene mutations, and two patients had detected HNF1B heterozygous mutations. Therefore, performing mutation analyses on only PKD1 and PKD2 in ADPKD patients who require gene diagnosis is insufficient, and application of our gene detection panel or even WES and MLPA are necessary (MLPA is a novel diagnostic tool for genetic screening, which is gradually becoming the principal method for the detection of exon deletion and duplication (Schouten et al., [2002](#mgg3720-bib-0037){ref-type="ref"}), as they can detect HNF1B, gene repetition and deletion, or other possible pathogenic gene mutations. Currently, PKDB describes 2323 PKD1 mutations and 278 PKD2 mutations. We detected 42 PKD1 mutation sites (87.5%) and six PKD2 mutation sites (12.5%), which were similar to percentages previously reported in the literature. Among 44 bilateral PKD patients, the PKD1 (p.G3560R) missense mutation was detected in five families. This site might be a neutral site. We speculated that this mutation site had greater prevalence in the Chinese population. The pathogenicity of the novel mutation sites discovered in this study must be confirmed in other families in future studies. We detected no large gene deletions or repetitions in this patient group, which might be due to the limitations of NGS. We discovered 16 novel PKD1 gene mutation sites and two novel PKD2 gene mutation sites in the Chinese population, which could enrich the ADPKD Mutation Database.

The onset of ADPKD caused by PKD1 and/or PKD2 gene mutations and the severity of their phenotypes are not only associated with gene mutations (germ cell mutations) but are also associated with somatic cell mutations or deletions in normal alleles caused by environmental factors such as toxins and infection (Feng, Watnick, Onuchic, & Germino, [1996](#mgg3720-bib-0010){ref-type="ref"}). ADPKD caused by PKD1 and/or PKD2 mutations is usually bilateral. Its phenotypes are associated with patient gender, whether the patient has hypertension or had a urologic event (gross hematuria, flank pain, or cyst infection) before age 35, and gene mutation characteristics (genotypes)(Cornec‐Le et al., [2016](#mgg3720-bib-0008){ref-type="ref"}; Jin et al., [2016](#mgg3720-bib-0018){ref-type="ref"}). The average age of ERSD onset caused by PKD1 mutations is 54.3 years, while the average age of ERSD onset caused by PKD2 mutations is 74 years (Kurashige et al., [2015](#mgg3720-bib-0019){ref-type="ref"}). Because the average age of this patient group was 39.4 years and most patients had not reached the above ages, most patients had normal kidney functions. We have not performed genotype‐phenotype analyses on these patients; however, we will continue to monitor them and further perform genotype‐phenotype analyses.

The HNF1B gene \[MIM 189907\] that causes the phenotype similar to polycystic kidneys is transcription factor 2 located on chromosome 17q12. HNF1B can directly regulate PKHD1 transcription. Inhibiting PKHD1 gene expression may result in human renal cyst formation (Hiesberger et al., [2004](#mgg3720-bib-0015){ref-type="ref"}). HNF1B\'s effects on the kidneys may include renal cysts, solitary kidney, horseshoe kidney, renal dysplasia, and hydronephrosis (Clissold, Hamilton, Hattersley, Ellard, & Bingham, [2015](#mgg3720-bib-0007){ref-type="ref"}). Renal cysts caused by HNF1B mutations are more heterogeneous; they can present as multiple, few, or no cysts, and some patients will enter into ESRD (Faguer et al., [2011](#mgg3720-bib-0009){ref-type="ref"}). The severity of the HNF1B mutation‐associated kidney disease phenotype had no clear association with the genotype (Heidet et al., [2010](#mgg3720-bib-0014){ref-type="ref"}). We detected HNF1B heterozygous mutations in three patients. Two patients had bilateral PKD, and their HNF1B mutations were both large mutations (P43 had a complete deletion and P44 had a frameshift mutation). We speculated that these 2 patients' bilateral PKD diseases were caused by HNF1B mutations. P45 had unilateral PKD with a point mutation in HNF1B. We found that the gene mutation levels of these three patients might be related to the kidney phenotype, which was more severe in patients with large mutations and was inconsistent with previous study results. This difference may have been due to our fewer patients. After a larger number of patients with PKD caused by HNF1B mutations is increased, whether kidney phenotype is associated with genotype can be further analyzed. The association between HNF1B mutations and unilateral PKD remains unclear. Mutations in the HNF1B gene usually cause diabetes maturity‐onset diabetes of the young type 5 (MODY5) (Roehlen et al., [2018](#mgg3720-bib-0033){ref-type="ref"}). Of the three patients with the HNF1B mutation we detected, P44 (32 years old) had type 2 diabetes, while P43 (56 years old) and P45 (39 years old) had no diabetes. The incidence of diabetes in these three patients did not show age‐related. The phenotype caused by HNF1B mutations is diverse and does not necessarily lead to the onset of diabetes (Chen et al., [2010](#mgg3720-bib-0005){ref-type="ref"}). Even mutations at the same site show multiple phenotypes (Yorifuji et al., [2004](#mgg3720-bib-0041){ref-type="ref"}). The father of P45 also had an HNF1B mutation, however, he did not have diabetes mellitus or renal structural abnormalities, and we have not functionally validated this mutation site. Therefore, the significance of this mutation site on renal cyst development is unclear. Further larger studies would be required to confirm whether HNF1B mutations are associated with unilateral PKD.

Unilateral PKD is rare, as are studies of it. Among the three cases of unilateral PKD discovered in this study, P45's case may have been caused by an HNF1B mutation, while P46 and P47 had no gene mutations on the kidney disease panel and P47 had LYZ, FGA, and GLI3 heterozygous mutations on the WES. These three genes have not been reported to be associated with PKD in the past, and this patient had no clinical presentations associated with these three genotypes. Whether unilateral PKD is associated with the above genes requires further confirmation using further larger studies.

In conclusion, using our developed targeted NGS panel for gene detection is necessary for PKD patients. It can be used to confirm patient genotypes (with/without mutations, mutation numbers, and mutation types) and has important significance in confirming molecular diagnoses and predicting patient prognosis. Targeted NGS panel and WES on unilateral PKD patients are significant. Macromutation in HNF1B may lead to bilateral PKD. While the relationship between HNF1B and unilateral PKD needs further studies to confirm. We discovered 16 novel PKD1 gene mutation sites and two novel PKD2 gene mutation sites that can enrich the PKDB and are significant in genetic counseling for ADPKD patients, and the use of effective targeted NGS method in the molecular diagnosis of ADPKD will increase the number of studied families and expand the mutation database of ADPKD.

CONFLICT OF INTEREST {#mgg3720-sec-0017}
====================

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT {#mgg3720-sec-0019}
===========================

The datasets used and analyzed during the current study available from the corresponding author on reasonable request.

Supporting information
======================

###### 

 

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.

This work was supported by the National Natural Science Foundation of China (No. 81570597, and No. 81330019) and the Ministry of Science Technology of China (grant No. 2011CB944000).
